Form 4: OPKO Health CEO Boosts Stake with $750K Share Purchase

Phillip Frost, CEO and Chairman of OPKO Health, acquired 570,000 shares of common stock through trusts, signaling increased insider confidence.

Summary

• Phillip Frost, MD, CEO and Chairman of OPKO Health, Inc., and a 10% owner, reported the acquisition of 570,000 shares of common stock.
• The shares were purchased on November 20, 2025, through Frost Gamma Investments Trust.
• The purchase prices ranged from $1.32 to $1.35 per share.
• The total value of the acquired shares is approximately $758,100.
• Following these transactions, the beneficial ownership of common stock through Frost Gamma Investments Trust increased to 216,126,448 shares.
• The report also notes a disposal of 3,568,951 direct common shares, though without a specific transaction date or price detailed in this filing.
• An additional 30,127,177 shares are beneficially owned indirectly through Frost Nevada Investments Trust.

Sentiment

Score: 8

Explanation: The significant insider buying by the CEO and Chairman, Phillip Frost, MD, indicates strong confidence in the company's future prospects. While there's a mention of a disposal of direct shares, the substantial purchases outweigh this, suggesting a positive outlook from a key insider.

Positives

• Phillip Frost, a key insider (CEO, Chairman, 10% owner), acquired a significant number of shares (570,000 shares), indicating strong confidence in the company's future prospects.
• The total value of the insider purchases amounts to approximately $758,100, representing a substantial personal investment.
• Insider buying can often be interpreted by the market as a positive signal, suggesting that management believes the stock is undervalued or expects positive developments.

Negatives

• The report notes a disposal of 3,568,951 direct common shares, which, without further context on the transaction date or reason, could be viewed as a negative, though it is overshadowed by the significant purchases.

Future Outlook

NA

Industry Context

Insider buying by a CEO and Chairman in the biotechnology and pharmaceutical sector can signal confidence in upcoming clinical trial results, regulatory approvals, or product launches, which are critical value drivers in this industry. It suggests a belief that the company's current valuation does not fully reflect its future potential, especially given the long development cycles and high R&D costs typical of the sector.

Related Party Transactions

• The acquired securities are held by Frost Gamma Investments Trust, where Phillip Frost, M.D., serves as trustee.
• Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust, and Dr. Frost is one of two limited partners of Frost Gamma L.P.
• The general partner of Frost Gamma L.P. is Frost Gamma, Inc., with Frost-Nevada Corporation as its sole shareholder, and Dr. Frost is the sole shareholder of Frost-Nevada Corporation.
• An additional 30,127,177 shares are held by Frost Nevada Investments Trust, where Dr. Frost is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. Dr. Frost is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P.
• Dr. Frost disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein.

Stakeholder Impact

• Shareholders may view the insider buying as a strong vote of confidence from the CEO and Chairman, potentially leading to increased investor interest and positive sentiment.
• Employees could interpret the insider's investment as a sign of stability and positive future outlook for the company.
• Creditors may see the insider's commitment as a positive indicator of the company's long-term viability.

Key Dates

Recommendation

The substantial open-market purchases by Phillip Frost, MD, the CEO, Chairman, and a 10% owner, totaling approximately $758,100, represent a significant vote of confidence from a highly informed insider. Such insider buying often signals that management believes the company's stock is undervalued and expects positive future developments. While a disposal of direct shares is noted, the clear and substantial acquisitions outweigh this, suggesting a strong conviction in OPKO Health's prospects. This action by a key executive typically serves as a bullish indicator for seasoned investors.

Keywords

OPKO Health, OPK, Phillip Frost, Insider Buying, Form 4, Share Purchase, CEO, Chairman, Beneficial Ownership, Stock Acquisition, Biotechnology, Pharmaceuticals